Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNOV 
MediciNova Inc (MNOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MNOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.83% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.31M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.44 | 52 Weeks Range 1.13 - 2.55 | Updated Date 10/17/2025 |
52 Weeks Range 1.13 - 2.55 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2679.88% |
Management Effectiveness
Return on Assets (TTM) -15.09% | Return on Equity (TTM) -22.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26859588 | Price to Sales(TTM) 455.48 |
Enterprise Value 26859588 | Price to Sales(TTM) 455.48 | ||
Enterprise Value to Revenue 199.55 | Enterprise Value to EBITDA -2.65 | Shares Outstanding 49046246 | Shares Floating 42081189 |
Shares Outstanding 49046246 | Shares Floating 42081189 | ||
Percent Insiders 2.98 | Percent Institutions 21.82 |
Upturn AI SWOT
MediciNova Inc
Company Overview
History and Background
MediciNova, Inc. is a biopharmaceutical company founded in 2000. It focuses on acquiring and developing novel, small-molecule therapeutics for unmet medical needs, primarily in neurological, inflammatory, and fibrotic diseases. It has achieved several milestones in clinical trials and drug development over the years.
Core Business Areas
- Neurology: Development of therapies for neurological disorders such as multiple sclerosis, amyotrophic lateral sclerosis (ALS), and other neurological conditions.
- Inflammation and Fibrosis: Development of therapies for inflammatory and fibrotic diseases, including nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
Leadership and Structure
MediciNova's leadership team includes Yuichi Iwaki, M.D., Ph.D., President and CEO. The company has a typical corporate structure with departments for research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Ibudilast (MN-166): Ibudilast is MediciNova's lead product candidate being developed for various indications including progressive MS, ALS and other indications. There is no market share data because none of these have been approved for sale. Competitors depend on indication. For MS, competitors include Biogen, Novartis, and Roche. For ALS, competitors include Amylyx Pharmaceuticals and Mitsubishi Tanabe Pharma.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, high regulatory hurdles, and significant competition. The industry is driven by the need for innovative therapies to address unmet medical needs.
Positioning
MediciNova is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics. Its competitive advantage lies in its diversified pipeline and focus on niche indications.
Total Addressable Market (TAM)
The TAM for the diseases MediciNova is targeting, such as MS, ALS, and NASH, is substantial, potentially reaching billions of dollars. MediciNova is positioned to capture a portion of this market if its drug candidates are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Diversified pipeline
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of commercialization infrastructure
- Limited revenue
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
- Orphan drug designations
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- RHHBY
- AMLY
Competitive Landscape
MediciNova faces competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its novel drug candidates and focus on niche indications.
Growth Trajectory and Initiatives
Historical Growth: MediciNova's historical growth has been driven by its progress in clinical trials and its ability to secure funding.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for Ibudilast in various indications and seeking partnerships to support development and commercialization efforts.
Summary
MediciNova is a clinical-stage biopharmaceutical company with a promising pipeline of novel therapies. Its success hinges on positive clinical trial results and securing partnerships for commercialization. The company faces challenges related to funding, regulatory hurdles, and competition from larger players. Ibudilast is the company's main prospect.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MediciNova's website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MediciNova Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2005-02-08 | Co-Founder, President, CEO & Chairman Dr. Yuichi Iwaki M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://medicinova.com |
Full time employees 13 | Website https://medicinova.com | ||
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.